SCHEMBL6897927

SCHEMBL6897927

CC(C)(C)OC(=O)CNC(=O)N(CCO)CCC1CCCCC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 3/20 0.36
CTSS P25774 1/20 0.36
CTSK P43235 1/20 0.36
CASR P41180 1/20 0.35
EPHX2 P34913 1/20 0.34
MAPT P10636 2/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
ATM Q13315 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.32
BCHE P06276 1/20 0.32
GAA P10253 1/20 0.32
PPARG P37231 2/20 0.31
PPARA Q07869 2/20 0.31
GMNN O75496 1/20 0.31
USP2 O75604 1/20 0.31
USP1 O94782 1/20 0.31
ALDH1A1 P00352 1/20 0.31
LMNA P02545 1/20 0.31
TP53 P04637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6898719 0.84 CASR (0.33) EPHX1CTSSCTSKCASREPHX2
SCHEMBL1845894 0.81 CA14 (0.40) EPHX1CTSSCTSKCASRMAPT
SCHEMBL27538336 0.79 METAP2 (0.38) CTSSCTSKCASRKMT2AFKBP1A
SCHEMBL27576386 0.79 METAP2 (0.38) CTSSCTSKCASRKMT2AFKBP1A
SCHEMBL27538282 0.79 METAP2 (0.38) CTSSCTSKCASRKMT2AFKBP1A
SCHEMBL27570927 0.78 PPARA (0.36) EPHX1CTSSCTSKCASRMAPT
SCHEMBL27562663 0.78 METAP2 (0.37) CTSSCTSKCASRKMT2AALDH1A1
SCHEMBL27562664 0.78 METAP2 (0.37) CTSSCTSKCASRKMT2AALDH1A1
SCHEMBL6731438 0.77 PKM (0.41) EPHX1CASRKMT2AALDH1A1LMNA
SCHEMBL6737845 0.76 SIGMAR1 (0.46) EPHX1CASRBCHEALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6730784-B2 AS THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2004-05-04 US disclosed
US-20020198376-A1 Novel urea derivatives SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-12-26 US disclosed
US-6492370-B1 Urea derivatives and pharmaceutical compositions thereof SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-12-10 US disclosed
CN-1299344-A Novel urea derivatives SANTEN PHARCEUMATICAL CO LTD (JP) 2001-06-13 CN disclosed
EP-1072591-A1 NOVEL UREA DERIVATIVES SANTEN PHARMACEUTICAL CO., LTD. (JP) 2001-01-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020198376-A1 Novel urea derivatives TNF, CTH, CFH EPHX1 984/4885CTSS 625/4885CTSK 1877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.